Side-by-side · Research reference
CardiogenvsFollistatin-344
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED5/46 cited
BHuman-MechanisticHUMAN-REVIEWED4/58 cited
Cardiogen
Bioregulator · Cardiac
CardiacTissue target
Gene regulationMechanism
AnimalEvidence level
SQ · Variable protocols
Follistatin-344
Myostatin/Activin Antagonist · Research Use
15–25%FST/MSTN ratio ↑
344 AACirculating isoform
ResearchPhase status
Research · No approved protocol
01Mechanism of Action
Parameter
Cardiogen
Follistatin-344
Pathway
Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022
FST-344 binds MSTN/Activin → prevents ActRIIB receptor engagement → disinhibits muscle anabolism
Downstream effect
Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue
Elevated follistatin/myostatin ratio, increased muscle protein synthesis, attenuated muscle atrophy signalingJeong 2026
Feedback intact?
Presumed — peptide bioregulators act via gene regulation, not receptor agonism
Yes — indirect antagonist, preserves endogenous regulation
Origin
Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology
Endogenous glycoprotein, 344-AA isoform lacking heparin-binding domain (vs FST-315)
Antibody development
—
Not documented in available trials (endogenous protein)
02Dosage Protocols
Parameter
Cardiogen
Follistatin-344
Standard dose
Variable — typically 10–20 mg per course
No standardised human protocol; animal-derived dosing.
—
Frequency
Intermittent courses — 10–20 days, repeated periodically
Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.
—
Evidence basis
Animal models / mechanistic studies
No Phase 1+ human trials in PubMed.
Human observational / biomarker studies
Route
Subcutaneous injection
—
Duration
10–20 day courses, repeated 2–4× per year
Russian geriatric protocols; unclear extrapolation to general populations.
—
Clinical protocol
—
None — no approved dosing regimen
Follistatin-344 measured as endogenous biomarker, not administered exogenously in cited trials.
Research context
—
Endogenous modulation via exercise + nutrition
Resistance training + EAA intake elevated FST/MSTN ratio by 15–25% in 12-week RCT (older women).
Half-life
—
Not established
Circulating isoform; lacks tissue-binding domain of FST-315.
03Metabolic / Fat Loss Evidence
Parameter
Cardiogen
Follistatin-344
Primary target
—
Muscle mass preservation, not direct lipolysis
Indirect fat effect
—
Increased lean mass → elevated resting metabolic rate
Not primary mechanism. Muscle-sparing during deficit.
Clinical evidence
—
Lorcaserin trial (6 mo) showed no MAFI axis changes during fat lossRamirez-Cisneros 2026
Suggests follistatin not primary driver of fat loss in weight-reduction interventions.
GLP-1RA studies
—
Liraglutide (35 days) — no significant MAFI axis modulation despite fat/lean changes
04Side Effects & Safety
Parameter
Cardiogen
Follistatin-344
Injection site reactions
Mild erythema, induration (presumed)
—
Systemic adverse events
No documented serious AEs in available literature
Very limited safety data; no rigorous pharmacovigilance.
—
Immunogenicity
Unknown — no antibody development studies published
—
Long-term safety
Unknown — no extended human trials indexed in PubMed
—
Clinical safety data
—
None — no human exogenous administration trials in literature
Theoretical risks
—
Excessive myostatin inhibition → muscle overgrowth, impaired glucose tolerance
Based on myostatin-null animal models and clinical myostatin inhibitor trials.
Endogenous elevation (exercise)
—
No adverse effects reported in 12-week resistance + EAA trials
Cancer risk (theoretical)
—
Myostatin inhibition may promote tumor growth in malignancy (preclinical data)
Regulatory status
—
Not approved for human use — research peptide only
Absolute Contraindications
Cardiogen
- ·Active malignancy (theoretical peptide growth factor concern)
- ·Hypersensitivity to peptide components
Follistatin-344
- ·Active malignancy
- ·No approved protocol — research use only
Relative Contraindications
Cardiogen
- ·Acute cardiac events (no safety data in acute MI, unstable angina)
- ·Pregnancy / lactation (no reproductive toxicity data)
Follistatin-344
- ·Insulin resistance / Type 2 diabetes (monitor glucose)
- ·Pregnancy / lactation (unknown safety profile)
05Administration Protocol
Parameter
Cardiogen
Follistatin-344
1. Reconstitution
Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.
Follistatin-344 is not approved for human administration. All cited studies measure endogenous serum follistatin as a biomarker, not as an exogenous therapeutic agent.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.
Resistance exercise combined with essential amino acid (EAA) supplementation elevated the follistatin/myostatin ratio by 15–25% in 12-week randomized trials. Protein intake (1.2–1.5 g/kg/day) synergizes with training to upregulate endogenous follistatin.
3. Timing
Variable — often evening injection. No established circadian preference.
Serum follistatin and follistatin/myostatin ratio are used diagnostically in sarcopenia screening and as biomarkers of muscle anabolic balance in clinical trials.
4. Storage
Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.
Gene therapy and recombinant follistatin delivery are under preclinical investigation for muscular dystrophy and sarcopenia. No human safety or efficacy data for exogenous FST-344 administration.
5. Needle
27–30G insulin syringe, 45° angle for subcutaneous administration.
—
06Stack Synergy
Cardiogen
+ Thymalin
ModerateKhavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.
- Cardiogen
- 10–20 mg SQ · 10–20 day course
- Thymalin
- 10–30 mg IM · concurrent or sequential courses
- Frequency
- 2–4 courses per year
- Primary benefit
- Multi-system aging mitigation, cardiovascular and immune homeostasis
Follistatin-344
+ BPC-157
Multi-pathwayFollistatin-344 (myostatin antagonist) and BPC-157 (tissue repair peptide) address complementary pathways in muscle recovery. FST-344 promotes muscle protein synthesis by disinhibiting myostatin signaling, while BPC-157 accelerates healing of tendons, ligaments, and microtears via angiogenesis and collagen synthesis. Combined, they may support both hypertrophy and structural repair during high-volume training or injury recovery.
- Follistatin-344
- No approved protocol — endogenous modulation via resistance exercise + EAA
- BPC-157
- 250–500 mcg SQ · twice daily · near injury site or systemic
- Duration
- 4–8 weeks
- Primary benefit
- Muscle hypertrophy + accelerated soft tissue repair
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) promotes cell migration, angiogenesis, and anti-inflammatory signaling in muscle and connective tissue. Follistatin-344's anabolic signaling may synergize with TB-500's regenerative effects during muscle damage or overtraining, particularly in older adults where both myostatin inhibition and tissue repair are rate-limiting.
- Follistatin-344
- Endogenous upregulation (resistance training + protein)
- TB-500
- 2–5 mg SQ · twice weekly · loading phase 4 weeks, then maintenance
- Frequency
- Twice weekly TB-500, daily training stimulus for FST
- Primary benefit
- Enhanced recovery, reduced inflammation, muscle growth support